Plans To Develop Its Lead Drug Candidate, Piclidenoson, For Treatment Of Lowe Syndrome
24/08/2023 12:23
Aug 24 (Reuters) -
* CAN FITE BIOPHARMA LTD - PLANS TO DEVELOP ITS LEAD DRUG
CANDIDATE, PICLIDENOSON, FOR TREATMENT OF LOWE SYNDROME
Source text for Eikon: ID:nBw1SK37Ka
Further company coverage: CANF.TA
((reuters.briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage